肾上腺皮质癌患者接受米托坦治疗期间中枢性甲状腺功能减退常见:患病率与时间线
该研究回顾了蒙特利尔和圖卢兹两个学术中心1995至2020年间接受米托坦治疗的肾上腺皮质癌患者病历,分析治疗期间及之后的甲状腺功能参数。在66例可评估患者中,63例(95.5%)出现中枢性甲状腺功能减退,多数发生在治疗第一年,停用米托坦后65.4%的病例甲状腺功能部分或完全恢复。研究支持在米托坦治疗期间及停药后系统监测TSH和游离T4水平。
要点
- 米托坦治疗相关中枢性甲状腺功能减退患病率高达95.5%(63/66)。
- 多数病例发生在治疗第一年内,至少14.3%在暴露12个月后发生。
- 停用米托坦后65.4%的病例甲状腺功能部分或完全恢复。
核心结论
- 米托坦治疗常与新发中枢性甲状腺功能减退相关,患病率为95.5%。
- 大多数病例发生在治疗第一年。
- 65.4%的病例甲状腺功能部分或完全恢复。
- 本研究支持在米托坦治疗期间及停药后系统监测TSH和游离T4水平的重要性。
研究设计与样本
- 回顾性分析两个学术中心(加拿大蒙特利尔和法国圖卢兹)1995年至2020年间接受米托坦治疗的肾上腺皮质癌患者的医疗记录。
- 共纳入83例患者,排除17例因既存原发性甲状腺功能减退或药物诱导的甲状腺功能减退,最终分析66例。
主要发现
- 在66例患者中,3例维持正常甲状腺功能,63例发生中枢性甲状腺功能减退。
- 63例中,56例表现为不适当的正常或低TSH,7例表现为轻度升高的TSH。
- 甲状腺功能减退发生时间:<3个月占33.3%,3至6个月占19.1%,6至9个月占14.3%,9至12个月占9.5%。
- 至少14.3%的病例在暴露12个月后发生,6例发生时间不确定。
- 27例停用米托坦,其中部分恢复占42.3%,完全恢复占23.1%,主要发生在停用米托坦后前2年。
临床怎么用
- 作者认为,本研究支持在米托坦治疗期间及停药后系统监测TSH和游离T4水平的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited. OBJECTIVE: To better characterize thyroid hormone insufficiency in patients exposed to mitotane. METHODS: We reviewed medical records of patients from 2 academic centers in Montreal (Canada) and Toulouse (France) with exposure to mitotane therapy for adrenocortical cancer between 1995 and 2020. We analyzed the thyroid function parameters during and after treatment. RESULTS: In our cohort of 83 patients, 17 were excluded because of preexisting primary hypothyroidism or drug-induced hypothyroidism. During follow-up, 3/66 patients maintained a normal thyroid function and 63/66 developed central hypothyroidism. Among those 63 patients, 56 presented with an inappropriately normal or low TSH and 7 with a mildly elevated TSH. The onset of hypothyroidism was: <3 months in 33.3%, 3 to 6 months in 19.1%, 6 to 9 months in 14.3%, and 9 to 12 months in 9.5%. At least 14.3% of cases occurred after 12 months of exposure, and 6 patients had an undetermined time of occurrence. Over time, 27 patients stopped mitotane and partial (42.3%) or complete (23.1%) recovery from hypothyroidism was observed, mainly in the first 2 years after mitotane discontinuation. CONCLUSION: Mitotane therapy is frequently associated with new onset of central hypothyroidism with a prevalence of 95.5%. Most cases occurred in the first year of treatment. Partial or full recovery of thyroid function occurs in 65.4% of cases. This study supports the importance of systematic monitoring of TSH and free T4 levels during and following discontinuation of mitotane therapy.
引用
- Poirier J, Godemel S, Mourot A, et al. Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. J Clin Endocrinol Metab. 2023. PMID: 36856782. doi:10.1210/clinem/dgad115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。